#United Kingdom #Oxford #Cardiovascular Health #Caristo Diagnostics #CaRi-Heart

Caristo Diagnostics: A New Leader in Cardiovascular Innovations

Caristo Diagnostics has recently been recognized as a standout player in the field of cardiovascular diagnostics, taking home the prestigious Fierce Healthcare Innovation Awards for 2024. This accolade is a testament to the company's cutting-edge technology aimed at enhancing the prediction and early detection of cardiovascular diseases, prominently featuring its flagship product, the CaRi-Heart®.

Innovative Technology

The CaRi-Heart® solution leverages advanced artificial intelligence to analyze routine coronary computed tomography angiography (CCTA) scans. This method focuses on revealing coronary inflammation, a critical yet often overlooked contributor to heart attacks and strokes. Unlike traditional imaging methods that might miss these hidden risks, the CaRi-Heart® technology brings to light important data about patients’ cardiovascular health by quantifying inflammation levels more accurately than ever before.

Frank Cheng, CEO of Caristo Diagnostics, expressed his enthusiasm for the recognition, stating, "By revealing hidden coronary inflammation for the first time within existing cardiac scans, CaRi-Heart technology provides visibility into a key driver of coronary artery disease, helping physicians and patients to understand their risk."

Enhancing Patient Outcomes

The recognition by Fierce Healthcare underscores the potential of CaRi-Heart® to transform cardiovascular medicine. Caristo aspires to assist healthcare providers in taking proactive steps to mitigate risks. By improving the understanding of inflammatory processes in the coronary arteries, clinicians can make timely and informed interventions that lead to better patient management and outcomes. This proactive approach not only aims to enhance patient care but also has beneficial implications for healthcare systems and insurers in terms of economic value.

Growing Adoption of CCTA Exams

As cardiovascular disease remains a leading cause of death globally, the relevance of accurate diagnostics cannot be overstated. Recent statistics highlight an impressive 355% increase in the use of CCTA exams in outpatient settings between 2010 and 2019. This surge indicates a shift towards embracing advanced imaging techniques, particularly following the American Heart Association's recommendations in 2021 for front-line imaging. The increasing recognition of these technologies has resulted in heightened support from policymakers; for instance, Medicare doubled its reimbursements for CCTA exams in November 2024.

A Bright Future

Caristo Diagnostics is not resting on its laurels. Following the success of CaRi-Heart®, the company is actively developing new products with the aim of predicting additional health risks, including stroke and diabetes, well in advance. Such innovations promise to further position Caristo as a transformative force in the realm of diagnostics and preventive healthcare.

About Caristo Diagnostics

Founded in 2018 as a spin-off from the University of Oxford, Caristo Diagnostics has quickly established itself as a leading entity in cardiovascular disease diagnostics and risk prevention. With recognition from various authorities, including accolades by Newsweek and Nature, the company's commitment to innovation continues to drive its success in the medical technology landscape.

As healthcare systems worldwide strive for improvements in patient care and cost-effectiveness, Caristo Diagnostics stands at the forefront, poised to change the narrative in cardiovascular health diagnostics. With its focus on making invisible causes of heart disease visible, Caristo aims to enhance diagnostic precision and promote healthier outcomes for millions across the globe.